Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA/RNA methyltransferases. Azacitidine is incorporated into DNA and RNA following cellular uptake and enzymatic biotransformation to nucleotide triphosphates. Incorporation of Azacitidine into the DNA of cancer cells in vitro, including acute myeloid leukemia cells, inhibited DNA methyltransferases, reduced DNA methylation and altered gene expression, including re-expression of genes regulating tumor suppression and cell differentiation. Incorporation of Azacitidine into the RNA of cancer cells, including leukemic cells, inhibited RNA methyltransferases, reduced RNA methylation, decreased RNA stability and decreased protein synthesis. Antileukemic activity of Azacitidine was demonstrated by reduction of cell viability and induction of apoptosis in AML cell lines in vitro. Azacitidine decreased tumor burden and increased survival in leukemic tumor models in vivo.
Do not substitute Azacitidine for intravenous or subcutaneous Azacitidine. The indications and dosing regimen for Azacitidine differ from that of intravenous or subcutaneous Azacitidine. Recommended Dosage : The recommended dosage of Azacitidine is 300 mg orally once daily with or without food on Days 1 through 14 of each 28-day cycle. Continue Azacitidine until disease progression or unacceptable toxicity. Administer an antiemetic 30 minutes prior to each dose of Azacitidine for the first 2 cycles. Antiemetic prophylaxis may be omitted after 2 cycles if there has been no nausea and vomiting. If the absolute neutrophil count (ANC) is less than 0.5 Gi/L on Day 1 of a cycle, do not administer Azacitidine (Azacitidine). Delay the start of the cycle until the ANC is 0.5 Gi/L or more. Instruct patients on the following : Do not split, crush, or chew Azacitidine tablets. Take a dose about the same time each day. If a dose of Azacitidine is missed, or not taken at the usual time, take the dose as soon as possible on the same day, and resume the normal schedule the following day. Do not take 2 doses on the same day. If a dose is vomited, do not take another dose on the same day. Resume the normal schedule the following day. Azacitidine is a hazardous drug. Follow applicable special handling and disposal procedures. Monitoring and Dosage Modifications for Adverse Reactions : Monitor complete blood count every other week for the first 2 cycles and prior to the start of each cycle thereafter. Increase monitoring to every other week for the 2 cycles after any dose reduction for myelosuppression.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression. The following adverse reactions have been identified during postapproval use of intravenous or subcutaneous Azacitidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypersensitivity reaction Interstitial lung disease Tumor lysis syndrome Sweet’s syndrome (acute febrile neutrophilic dermatosis) Necrotizing fasciitis (including fatal cases) Differentiation syndrome
Azacitidine is contraindicated in patients with known severe hypersensitivity to Azacitidine.
Risks of Substitution with Other Azacitidine Products : Due to substantial differences in the pharmacokinetic parameters, the recommended dose and schedule for Azacitidine are different from those for the intravenous or subcutaneous Azacitidine products. Treatment of patients using intravenous or subcutaneous Azacitidine at the recommended dosage of Azacitidinemay result in a fatal adverse reaction. Treatment of patients using Azacitidine at the doses recommended for intravenous or subcutaneous Azacitidine may not be effective. Do not substitute Azacitidine for intravenous or subcutaneous Azacitidine. Myelosuppression : New or worsening Grade 3 or 4 neutropenia and thrombocytopenia occurred in 49% and 22% of patients who received Azacitidine, respectively. Febrile neutropenia occurred in 12%. A dose reduction was required for 7% and 2% of patients due to neutropenia and thrombocytopenia, respectively. Less than 1% of patients discontinued Azacitidine due to either neutropenia or thrombocytopenia. Monitor complete blood counts and modify the dosage as recommended. Provide standard supportive care, including hematopoietic growth factors, if myelosuppression occurs. Increased Early Mortality in Patients with Myelodysplastic Syndromes : In AZA-MDS-003 (NCT01566695), 216 patients with red blood cell transfusion-dependent anemia and thrombocytopenia due to myelodysplastic syndromes were randomized to Azacitidine or placebo. One hundred and seven patients received a median of 5 cycles of Azacitidine 300 mg daily for 21 days of a 28-day cycle. Enrollment was discontinued early due to a higher incidence of early fatal and/or serious adverse reactions in patients who received Azacitidine compared with placebo. The most frequent fatal adverse reaction was sepsis. The safety and effectiveness of Azacitidine for treatment of myelodysplastic syndromes have not been established. Treatment of patients with myelodysplastic syndromes with Azacitidine is not recommended outside of controlled trials. Embryo-Fetal Toxicity : Based on the mechanism of action and findings in animals, Azacitidine can cause fetal harm when administered to a pregnant woman. Azacitidine administered to pregnant rats via a single intraperitoneal dose less than the recommended human daily dose of oral Azacitidine on a mg/m2 basis caused fetal death and anomalies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Azacitidine and for at least 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Azacitidine and for at least 3 months after the last dose.